Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs...

Full description

Saved in:

Bibliographic Details
Main Authors:	R.-D. Hofheinz, U. Ronellenfitsch, S. Kubicka, A. Falcone, I. Burkholder, U. T. Hacker
Format:	Article
Language:	English
Published:	Wiley 2016-01-01
Series:	Gastroenterology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2016/9189483
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study
by: Qiong Yang, et al.
Published: (2025-07-01)

Comparative analysis of antiangiogenic and immunotherapeutic regimens in the treatment of metastatic pulmonary lymphoepithelioma-like carcinoma
by: Fu-Lian Qu, et al.
Published: (2025-07-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
by: Yan-xian Chen, et al.
Published: (2014-01-01)

Antiangiogenic Potential of Pomegranate Extracts
by: Riccardo Tornese, et al.
Published: (2024-11-01)

A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
by: Eric Nguyen-Khac, et al.
Published: (2013-01-01)

Mathematical model of the impact of chemotherapy and antiangiogenic therapy on drug resistance in glioma growth
by: Hanum Latifah, et al.
Published: (2025-04-01)

Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs
by: Ricardo Casaroli-Marano, et al.
Published: (2014-01-01)

Antiangiogenic VEGF Isoform in Inflammatory Myopathies
by: Nila Volpi, et al.
Published: (2013-01-01)

Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements
by: Ke-Qiang Hou, et al.
Published: (2025-07-01)

Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
by: V. G. Likhvantseva, et al.
Published: (2024-04-01)

MODERN IDEAS ABOUT THE COMBINATION OF RADIATION THERAPY WITH ANTIANGIOGENIC DRUGS IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES
by: O. I. Kit, et al.
Published: (2020-03-01)

Efficiency of antiangiogenic therapy for choroidal neovascularization in children
by: L. A. Katargina, et al.
Published: (2024-12-01)

Future Perspectives for Antiangiogenic Therapy in Retinal Diseases
by: M. V. Budzinskaya, et al.
Published: (2021-10-01)

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
by: Ambra Pozzi, et al.
Published: (2008-01-01)

Antiangiogenic activity of 2-deoxy-D-glucose.
by: Jaime R Merchan, et al.
Published: (2010-10-01)

Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials
by: Xiaojun Yuan, et al.
Published: (2025-07-01)

Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT.
by: Chengyu Sun, et al.
Published: (2024-01-01)

Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis
by: Shaoqing Fan, et al.
Published: (2025-04-01)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
by: Tetsuro Kawagoe, et al.
Published: (2020-01-01)

Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis
by: D. V. Garbuzenko
Published: (2018-11-01)

The dose-dependent antiangiogenic potential of apixaban: an experimental outlook
by: Özgür Akkaya, et al.
Published: (2022-08-01)

Numerical Simulation of Solid Tumor Blood Perfusion and Drug Delivery during the “Vascular Normalization Window” with Antiangiogenic Therapy
by: Jie Lv, et al.
Published: (2011-01-01)

An In Vitro-In Vivo Evaluation of the Antiproliferative and Antiangiogenic Effect of Flavone Apigenin against SK-MEL-24 Human Melanoma Cell Line
by: Alexandra Ghiƫu, et al.
Published: (2021-01-01)

MATHEMATICS MODEL OF COMPACT TUMOR TO ANALYZE THE EFFECT ANTIANGIOGENIC THERAPY
by: Eristia Arfi, et al.
Published: (2024-07-01)

Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience
by: Jungić Saša, et al.
Published: (2022-01-01)

Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal carcer
by: Jungić Saša, et al.
Published: (2017-01-01)

When cardiotoxicity demonstrated in Cardio-oncology is investigated in other contexts: Research into the cardiovascular effects of antiangiogenic drugs used in ophthalmology
by: Júlia Cristina Toste
Published: (2025-01-01)

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis
by: Chengjun Wang, et al.
Published: (2025-06-01)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
by: Yinghui Xu, et al.
Published: (2023-02-01)

First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials
by: Yandong Xie, et al.
Published: (2025-07-01)

Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
by: Yi Xiao, et al.
Published: (2020-10-01)

Results of combined antiangiogenic activity on corneal neovascularization. Experimental and morphological study
by: V. R. Mamikpnyan, et al.
Published: (2014-09-01)

Natural products‐based antiangiogenic agents: New frontiers in cancer therapy
by: Tiago Azevedo, et al.
Published: (2024-11-01)

Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity
by: Chao Li, et al.
Published: (2024-12-01)

The efficacy of regorafenib monotherapy as the third-and later-line treatment for metastatic colorectal cancer: a retrospective study
by: An Tianqi, et al.
Published: (2022-08-01)

The efficacy and safety of chemoimmunotherapy in patients with MSI-L/MSS/pMMR status metastatic colorectal cancer: a systematic review and meta-analysis of randomized controlled trials
by: Qi-Jing Zhang, et al.
Published: (2025-06-01)

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials
by: Weiming Liang, et al.
Published: (2024-12-01)

Colorectal Cancer with Uncommon Metastatic Spread
by: Luca Dellavedova, et al.
Published: (2015-07-01)

Treatment sequencing in metastatic colorectal cancer
by: Nanteznta Torounidou, et al.
Published: (2025-01-01)